Founder and Former Chief Executive Officer and Chief Scientific Officer (5) · Candel Therapeutics, Inc. (CADL)

Estuardo Aguilar-Cordova

A named executive officer of Candel Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$526,386

Salary $520,192Stock awards $0

FY2020: $740,153

2nd of 3 named executive officers at Candel Therapeutics by FY2021 total.

3 named officers on file for Candel Therapeutics, FY2021

Estuardo Aguilar-Cordova’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Candel Therapeutics’s whole pay program stands against its peers

  • Candel Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CADL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed September 2, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Estuardo Aguilar-Cordova’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Estuardo Aguilar-Cordova compensation by year

Candel Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Candel Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$444,903$520,192
Bonus$104,000$0
Stock awards$0$0
Option awards$0$0
Non-equity incentive$191,250$0
Pension and deferred compensation$0$0
All other$0$6,194
Total$740,153$526,386

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Candel Therapeutics, Inc. DEF 14A filed September 2, 2022, accession 0001193125-22-237187, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Candel Therapeutics, Inc. filed document, accession 0001193125-22-237187. Every figure is read from that document and cited to the page and table it appears in. Filed September 2, 2022.

$740K
$526K
FY20
FY21
SalaryBonusNon-equity incentiveAll other

Insider transactions since the last proxy

44 Form 4 lines since the FY2021 proxy (filed September 2, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-02-21Disposition to the issuer—10,583$12.02162,929
2025-02-21Disposition to the issuer—10,582$12.02120,861
2025-02-10Disposition to the issuer—31,335$8.6160,000
2024-12-27Disposition to the issuer—50,000$8.85173,512
2024-12-27Disposition to the issuer—50,000$8.85131,443
2024-12-26Disposition to the issuer—50,000$9.01223,512
2024-12-26Disposition to the issuer—50,000$9.01181,443
2024-12-24Disposition to the issuer—50,000$8.82273,512

The 8 most recent of 44 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Candel Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Paul TakPresident and Chief Executive Officer$956,800
Estuardo Aguilar-Cordova · this pageFounder and Former Chief Executive Officer and Chief Scientific Officer (5)$526,386
John CanepaChief Financial Officer$449,123

Board service

Candel Therapeutics board · FY2023
Director compensation in US dollars, as Candel Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2023$35,000$0$13,186—$48,186

Each year as the company reported it in Candel Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Candel Therapeutics pays directors a $35,000 cash retainer. As stated in Candel Therapeutics's FY2023 proxy.

The full Candel Therapeutics compensation record

free company brief

This page is one person within Candel Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Candel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Estuardo Aguilar-Cordova's compensation dossier · One-time report. No refunds.